Exploring the Antimicrobial and Hepatoprotective Effects of Kefir; A Probiotic Fermented Milk

Sahar AbdEl-Mogheith¹, Ahmed Osama El-Gendy², Seragelddeen Sultan³ and Khalid A. El-Nesr⁴

¹Faculty of Post Graduate Studies for Advanced Sciences, Beni-Suef University, Beni-Suef 62511, Egypt.
²Faculty of Pharmacy, Microbiology and Immunology Department, Beni-Suef University, Beni-Suef 62511, Egypt.
³Faculty of Veterinary Medicine, Virology Division, Dep. of Microbiology, South Valley University, Qena 83523, Egypt.
⁴Faculty of Veterinary Medicine, department of pathology, Beni-Suef University, Beni-Suef 62511, Egypt.

http://dx.doi.org/10.22207/JPAM.11.2.15

(Received: 09 May 2017; accepted: 11 June 2017)

Fermented milk is considered as a good source of nutrition for many people. One of the most important substances that could be used in the fermentation of milk is kefir grains. Kefir fermented milk is very important in many health conditions such as bacterial infections, high blood pressure and some hepatic conditions. The aim of this study was to determine the antibacterial activity of fermented milk of kefir against certain pathogenic microorganisms such as Salmonella sp., Escherichia coli, Staphylococcus sp. and Candida albicans using agar diffusion method. The effectiveness of fermented milk of kefir has been studied as hepatoprotective against CCl₄ inducing liver toxicity and as a protective agent against kidney and spleen damage using laboratory animal models. The results revealed that the fermented milk of kefir had a potent antibacterial activity against many pathogenic microorganisms and it also showed significant high protection in mice against the toxicity of CCl₄. In conclusion, kefir milk can be used as an antibacterial supplement and as a protective agent against liver toxicity.

Keywords: Kefir, Antibacterial, Carbon tetrachloride; Liver toxicity, Milk.

“Kefir is gotten from the Turkish word “keif” which signifies “nice feeling”¹ and the drink started in the Caucasian heaps of Russia²³. Kefir is obtained from the fermenting activity of Kefir grains⁴. Traditionally, it is fermented in goatskin bags for 24 hours⁵. Kefir contains many ingredients that demonstrate biological activity, such as some probiotic bacteria and bioactive peptides⁶ and onsets of activity varies according to the type of kefir and the time of fermentation⁷. It is self-carbonated fermented milk with a slightly acidic taste⁸. The kefir drink is produced from cow, goat, sheep⁹, camel, buffalo or soy milk¹⁰ that could be whole fat, low-fat, skimmed or fat-free milk¹¹. This difference in the milk type and methods of fermentation affects the amount of grain produced, food composition and flavor of kefir¹². Kefir grains are considered to be the most important component in the production of fermented kefir and can be reused again¹³. It contains many types of bacteria in addition to proteins and polysaccharides¹⁴. Although the kefir drink can be found in many countries, in Egypt the grains are not commercially available and are culturally donated from person to person.
Partial sequencing of the gene encoding 16S rRNA was used for species identification\textsuperscript{14,15}. Fermented milk produced by kefir grains contains yeast and lactobacilli\textsuperscript{16,17,18}. Kefir has many applications in a variety of medical conditions such as; high blood pressure, allergy problems and coronary heart disease. Also, it strengthens the immune system and improves the digestive health. Kefir antimicrobial activity is associated with the production of organic acids, peptides (bacteriocins), carbon dioxide, hydrogen peroxide, ethanol and diacetyl\textsuperscript{15,19}.

The main objective of this study was to investigate the antimicrobial activity of the fermented kefir in vitro against different pathogens and to evaluate its hepatoprotective effect in mice.

\section*{MATERIALS AND METHODS}

\subsection*{Preparation and characterization of kefir}

Kefir grains were collected from Qena City, Egypt. They were varying in size (from 0.3 to 3.0 cm in diameter), irregular in shape\textsuperscript{20,21} as shown in (Fig. 1), and white to yellowish-white in color\textsuperscript{17,18,19}. Also, the grains were flexible, softer in texture, viscous\textsuperscript{12,17,18} and insoluble in water and common solvents. When milk was added, the grains swelled and produced a jellied called Kefiran\textsuperscript{22}. Kefir has a pH of 4.2 – 4.6, an ethanol content of 0.5 – 2.0\% (v/v), a lactic acid content of 0.8–1.0\% (m/v), a carbon dioxide content of 0.08 – 0.2\% (v/v)\textsuperscript{23}. The grains were recovered by sieving, mass of grain increased by 6\% after the fermentation process and microorganisms found in the milk are different from those produced after the fermentation process\textsuperscript{15,22}.

Kefiran was prepared by adding 100 g of kefir grains to 500 ml of purified milk at 25\degree C in a dark place for 24 h - 48 h. Kefir grains were separated from the fermented milk by plastic sieve\textsuperscript{24,25}.

The antimicrobial activity of the fermented kefir

Screening for antibacterial activity of the Kefir fermented milk was done using agar diffusion method (26, 27) against Gram-positive bacteria (\textit{Staphylococcus aureus} ATCC 44330 and \textit{Bacillus subtilis}), Gram-negative bacteria (\textit{Escherichia coli} ATCC 5087, \textit{Salmonella enteritidis} and \textit{Pseudomonas aeruginosa}), and yeast (\textit{Candida albicans}).

The Kefir fermented milk was filter sterilized using 0.45 \textmu m membrane filter and the indicator microorganisms were incubated overnight in brain heart infusion broth (Oxide) at 37\degree C. The antimicrobial activity was done based on seeding inoculation of each indicator microorganism in 20 ml Muller Hinton agar (Oxide), and then cups were prepared using Wassermann tubes with an external diameter of 5 mm. A fixed amount of 50 \textmu l, 100 \textmu l and 150 \textmu l of tested kefir solution was distributed to each well. The plates were incubated for 24 h at 37\degree C. A positive control of antibiotic ampicillin (10 mg/ml) was also tested. Estimation of antimicrobial activities was done by measuring diameters of zone of inhibitions.

\subsection*{Identification of microorganisms isolated from fermented kefir by partially sequencing of 16S rRNA gene}

The Kefir fermented milk was plated on MRS agar (Oxide) and Brain heart agar (Oxide) for 2 days at 25\degree C to isolate major lactic acid bacteria and other microorganisms in kefir and then a DNA extraction was done followed by PCR and DNA sequencing.

\subsection*{Genomic DNA extraction and purification}

Genomic DNA extraction was done according to\textsuperscript{27} with some modifications. Briefly, a 1.5 ml of culture was centrifuged for 10 min at 3,000 g, the supernatant was discarded and the pellets were resuspended in 200 \textmu l spheroplast buffer (10\% sucrose, 25 mM Tris pH 8.4, 25 mM EDTA pH 8.0, 2 mg/mL lysozyme and 0.4 mg/ ml RNase A), vortexes and incubated at 37 \degree C for 10 minutes until cell lysis occurred. Then, 50 \textmu l of 5\% SDS (lysis buffer 1) and 5 M NaCl (lysis buffer 2) were added, mixed and incubated at 65\degree C for 5 minutes. A 100 \textmu l neutralizing buffer (60 ml 5M Potassium acetate, 11.5 ml glacial acetic acid, and 28.5 ml dH\textsubscript{2}O) was then added and put on ice for 5 min before centrifugation at 18,000 g at 4\degree C for 15 minutes. The supernatant (approximately 400 \textmu l) was transferred to a new tube, mixed with equal volume of isopropanol, left 5 minutes at room temperature and centrifuged at 18,000 g at room temperature for 15 minutes to precipitate the DNA. The resulting pellet was washed with 70\% ethanol by centrifugation at 18,000 g at room temperature for 5 minutes. The final pellet was air-dried and resuspended in 50 \textmu l 1 x TE buffer pH 8 and stored in the refrigerator at 4\degree C.
PCR amplification and sequencing of bacterial 16S rRNA gene

PCR was carried out in 50 µl reaction volume in sterile 200 µl PCR tube. The PCR reaction mixture consisted of 500 ng genomic DNA, 10 mM dNTPs mixture, 1 µl (20 µM of each primer); forward primer 5'-TAACACATGCAAGTCGAACG-3' and reverse primer 5'-AAACTYAAAKGAATTGACGG-3', 2.5 units of Taq DNA polymerase enzyme and 10 µl 5X reaction buffer. The PCR program included template denaturation at 94 ºC (3 min), followed by 34 cycles of denaturing at 94 ºC (30 sec.), annealing at 56 ºC (30 sec.), and extension at 72 ºC (60 sec.), and followed by completion of DNA synthesis at 72 ºC (5 min). Primers were removed from the final PCR product prior to sequencing using QIAquick PCR purification kit (QIAGEN, Germany). The PCR product of interest was detected and purified by agarose gel electrophoresis using 1% (w/v) agarose gels with reference to 1 kbp DNA ladder. DNA was sequenced using the ABI Prism BigDye terminator sequencing ready reaction kit version 3.1 and analyzed with the ABI Prism 3100 generic analyzer.

Sequence manipulation and phylogenetic analysis

Searching for DNA sequence homology was done using BLAST tool at NCBI database (www.ncbi.nlm.nih.gov/blast) in order to assess the degree of DNA similarity. Multiple sequence alignment and molecular phylogeny were constructed using MEGA7 software.

Evaluation of the protective ability of Kefir against carbon tetrachloride CCl₄-induced liver toxicity in mice

Animal grouping and treatment

Three weeks old, clinically healthy, female Swiss albino mice (n=40) weighting 26–30 g were randomly divided into 4 groups (10 mice/group) after 7 days adaptation. They were housed in stainless-steel wire-mesh cages (four in a cage), at 24±2°C temperature, 55% relative humidity and a 12 h light–dark cycle. The animals were provided a normal diet and tap water. The groups were separately treated for as following:

Group I, animals were sham-treated with 2 ml/kg distilled water through oral gavage, daily for 4 weeks; this group of animals served as the control.

Group II, animals were treated with 1.5 ml/kg body weight (b.w.) CCl₄ dissolved in 1.5 ml corn oil through oral gavage, daily for 4 weeks.

Group III, animals were treated with 1.5 ml/kg b.w. CCl₄ + 30 ml/kg b.w kefir through oral gavage, daily for 4 weeks.

Group IV, animals were treated with 30 ml/kg b.w. Kefir through oral gavage daily for 4 weeks.

Preparation of Fermented Kefir to feed animals

The compound was prepared by washing the kefir grains with distilled water and raw milk, after that heated to 90 ºC for 10 min in a water bath, then cooled to inoculation temperature (25 ºC) and 10% active kefir grains added. The mixture was placed in a plastic container with screen cloth as a cover and incubated at room temperature for 24–48 hrs. A plastic container is used because the acidity of fermented kefir may degrade metals such as aluminum and iron which could mix with the drink thereby causing harmful effects to the body. After fermentation, kefir grains were sieved by filtration through a plastic sieve and washed for another process. Kefir drink was maintained at 4 ± 1ºC for 24 h and then used for microbiological and chemical analyses before feeding the animals in group III, kefir samples which were stored for more than 3 days were not used. Animal treatment was continued for 4 weeks then the experiment was concluded and animals were killed under anesthesia, blood samples were collected and livers, kidneys and spleen were rapidly removed then weighted to calculate relative liver weight to body weight.

Biochemical analysis

Each blood sample was placed in dry clean centrifuge tube, and then centrifuged for 10 min at 3000 revolutions per minute (rpm) to separate the serum. Serum was carefully separated into clean dry Wasserman tubes by using a Pasteur pipette and used for determination of serum liver function tests; aspartate aminotransferase (AST) (biolab), alanine aminotransferase (ALT) (biolab) and alkaline phosphatase (ALP) (biolab) using standard techniques by manufactures.

Histopathological examination

Tissue samples were collected from liver, kidney and spleen of all animals (Group I-IV). These samples were fixed in neutral formalin solution 10% for 72 hrs., after that fixed samples were processed and stained by Hematoxylin and Eosin according to.
RESULTS

The antibiotic activity of kefir against pathogenic microorganisms

Antibacterial activity of kefir, freshly fermented for 24 hrs and 48 hrs or stored for 72 hours at 4 - 8°C, was estimated by agar diffusion method. It was noted that Kefir has antibacterial activity against *Staphylococcus aureus*, *E. coli* and *Salmonella enteritidis*. For *E. coli* and *S. enteritidis*, the antimicrobial activity was superior to control antibiotics. The tested products exhibited no activity against *P. aeruginosa* and *C. albicans*. The results demonstrated that kefir possesses high antibacterial potentials against Gram-negative and Gram-positive strains (Fig. 2).

Microorganisms identification by partially sequencing the 16S rRNA and phylogenetic analysis

Identification of isolates to the species level was based on sequencing of 16S rRNA gene. The PCR of 16S rRNA gene using specific primers was done and revealed positive reactions and correct amplicon sizes. DNA sequencing was done and the obtained sequences were analyzed using both Bioedit v. 7.0.9.0 and CLC sequence analyzer programs. The homology search of the obtained sequences using BLAST tool at NCBI database was done to categorize the microorganisms to the closest species as in (Table 1). The isolated microorganisms were identified as *Micrococcus cohnii* (isolate ID SK14), *Lactobacillus kefiranofaciens* ZW3 (isolate ID SK22) and *Lactobacillus casei* strain KF11 (isolate ID SK23).

The resulted sequences were aligned to the closely related microorganisms by retrieving their sequences from the NCBI GenBank database and assembled in MEGA7 software for phylogenetic analysis using the Neighbor-Joining method and the evolutionary distances were computed using the Kimura 2-parameter method as seen in (Fig. 3).

Protective effect of Kefir against risk of carbon tetrachloride-induced liver toxicity and other damages in mice

Effect of treatment on body weight and relative liver weight

Effect of treatment on body weight and relative liver weight to body weight were estimated as illustrated in (Table 2); the ratio of liver weight

| Strain ID | Product size | Closest isolate | Accession number | Max number | Total score | Query score | E value | Max ident |
|-----------|--------------|-----------------|------------------|------------|-------------|-------------|---------|-----------|
| SK14      | 390 bp       | *Micrococcus cohnii* strain WS4601 | NR_117194.1       | 217        | 217         | 91%         | 4.00E-56 | 78%       |
| SK22      | 560 bp       | *Lactobacillus kefiranofaciens* ZW3, *Lactobacillus casei* strain KF11 | CP002764.1       | 2874       | 11492       | 100%        | 0       | 99%       |
| SK23      | 518 bp       |                 | KR816166.1       | 957        | 957         | 100%        | 0       | 100%      |

Table 2. Effects of kefir on liver weights and total body weights of mice treated with carbon tetrachloride (CCl₄) at the end of study (4 weeks)

| Treatment Groups | Liver weight/100g body weight | Body weight (% of initials) |
|------------------|-------------------------------|-----------------------------|
| Control          | 1.1070 (n=10) ± 0.04842       | 27.200 (n=10) ± 0.48419     |
| Kefir            | 1.1190 (n=10) ± 0.04656       | 27.3100(n=10) ± 0.58356     |
| CCl4             | 1.9990 (n=5) ± 0.13565 <sup>a</sup><sup>b</sup> | 22.3000 (n=5) ± 0.96954 <sup>a</sup><sup>b</sup> |
| Combination      | 1.3900 (n=5) ± 0.08741 <sup>a</sup><sup>bc</sup> | 24.4000 (n=5) ± 0.87178 <sup>a</sup><sup>bc</sup> |
| Total            | 1.3103 (n=30) ± 0.06545       | 25.9533 (n=30) ± 0.47766    |

Data are presented as mean ± standard error of 10 animals/group.

<sup>a</sup> Significantly different from control value at p < 0.05.
<sup>b</sup> Significantly different from Kefir value at p < 0.05.
<sup>bc</sup> Significantly different from CCl4 value at p < 0.05.
Table 3. Effect of kefir and carbon tetrachloride on liver function test (AST, ALT and ALP) in mice after four weeks of treatment

| Treatment Groups | AST (IU/L)          | ALT (IU/L)          | ALP (IU/L)          |
|------------------|---------------------|---------------------|---------------------|
| Control          | 38.1200 (n= 10 ) ±  | 45.0820 (n= 10 ) ±  | 67.8300 (n= 10 ) ±  |
|                  | 0.06255             | 0.80311             | 0.50400             |
| Kefir            | 39.3470 (n= 10 ) ±  | 46.4830 (n= 10 ) ±  | 68.5500 (n= 10 ) ±  |
|                  | 0.35139             | 0.43301             | 0.56239             |
| CCl₄             | 1372.6367 (n= 6) ±   | 1410.2500 (n= 6) ±  | 251.4583 (n= 6) ±   |
|                  | 2.06498             | 2.60688             | 16.79796            |
| Combination      | 561.5050 (n= 6) ±   | 472.8833 (n= 6) ±   | 112.5600 (n= 6) ±   |
|                  | 2.79362             | 1.85210             | 2.62721             |
| Total            | 386.8600 (n= 32 ) ± | 381.7016 (n= 32 ) ± | 110.8722 (n= 32 ) ± |
|                  | 92.22711            | 93.40436            | 12.84858            |

*Significantly different from control value at p < 0.05.
**Significantly different from Kefir value at p < 0.05.
***Significantly different from CCl₄ value at p < 0.05.

Data were calculated as relative weight of liver to 100 g animal body weight at the end of the experiment. Data are presented as mean ± standard error of 10 animals/group.

a, b or c indicates significant difference from control, kefir or corresponding initial body weight respectively at p ≤ 0.05 using Tukey’s test as post ANOVA test and as showing in (Fig. 4).

Effect of treatment on liver function

The serum levels of liver functions (AST, ALT, and ALP) are presented in (Table 3). In the CCl₄ treated group, the serum levels of AST, ALT, and ALP p < 0.05, increased to 1372.6367 ± 2.06498, 1410.2500 ± 2.60688 and 251.4583 ± 16.79796 respectively compared to negative control group values of 38.1200±.60255, 45.0820±.80311 and 67.8300±.50400 respectively. The pretreatment of CCl₄-treated mice with kefir significantly p <0.05, decreased the CCl₄ induced elevation of these markers levels to 561.5050±2.79362, 472.8833±1.85210, 112.5600 ±2.62721, respectively. Interestingly, kefir administration does not exhibit any significant change from control values of liver functions that is mean the Kefir protects liver against carbon tetrachloride as showing in (Fig. 5).

- Data were presented as mean ± standard error of 10 animals/group.
- a, b or c indicates significant difference from control, kefir or CCl₄ respectively at p <0.05 using Tukey’s test as post ANOVA test.
Histopathological examination

Liver

Control group
In the control group, the liver was histologically normal without noticeable alterations (Fig. 6a) with well demarcated hexagonal lobules having a central vein with normal portal traits containing artery, vein and bile ducts. The hepatocytes within the hepatic lobules were arranged in cords radiating around the central veins.

Fig. 2. The antimicrobial activity of fermented kefir after 24hr, 48hr and 72 hr against E. coli, Salmonella enteritidis and Staphylococcus aureus in compared to Ampicillin.

Fig. 3. Phylogenetic tree of the fermented kefir derived isolates based on partial 16S rRNA gene sequences. The phylogenetic tree was inferred using the Neighbor-Joining method (43). The distances were computed using the Kimura 2-parameter method (44) and are in the units of the number of base substitutions per site. Numbers at nodes indicate percentages of 1000 bootstrap re-samplings. Codon positions included were 1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were eliminated. Evolutionary analyses were conducted in MEGA7 (45).
and separated by hepatic sinusoids.

**Carbon tetrachloride (CCl4) group**

In this group, the liver of the animal showed variable degrees of degeneration, necrosis and inflammation. Moderate to severe vacuolation of hepatocytes (hydropic degeneration to fatty changes) were seen especially at the periphery of the lobules (Fig. 6b), in contrast to those around central veins which appeared normal. Mild to moderate sinusoidal dilatation with active proliferation of van Kupffer cells were noticed in most animals (Fig. 6c). Necrotic changes accompanied with fatty changes were also found in some areas; in which the hepatocytes had pyknotic nuclei with strong eosinophilic cytoplasm or severe destruction (Fig. 6d). Mild to moderate portal tracts and hepatic parenchyma infiltration with leucocytes was evident (Fig. 6e) with congested blood vessels.

**In CCl4-kefir treated group**

Histopathological examinations proved mild to moderate improvements in the form of absence of hepatic necrosis, however, some cells showed degenerative changes (Fig. 6f &g). Sings of regeneration was noticed in some areas as some cells showed mitotic activities and binucleation.
in others. The hepatic sinusoids appeared also of normal appearance with mild congestion was seen in some animals. Compared to the CCl$_4$ treated animals, much less damage could be seen

Fig. 6. Photomicrographs of hematoxylin and eosin stained histological section of (a) normal liver, (b) CCl$_4$–treated animals showing variable degrees of vacuolar degeneration, (c) CCl$_4$–treated animals showing widened sinusoids, active proliferated Von kupffer cells, (d) CCl$_4$–treated animals showing necrotic changes in the form of severe destruction of hepatocytes or karyolysis, (e) CCl$_4$–treated animals showing leucocytic infiltration in the portal area and hepatic parenchyma, (f) CCl$_4$–kefir treated animal showing much less damages in the hepatic parenchyma, more or less normal hepatocytes, and (g) CCl$_4$–kefir treated animal showing very mild vacuolar degeneration with no evidence of necrosis, mild congestion and no inflammatory changes

J PURE APPL MICROBIO, 11(2), JUNE 2017.
especially in the peri-central hepatic cells with mild inflammatory changes.

**Kidneys**

**Control group**

The renal tissue of this group appeared of normal structure especially the renal cortex (Fig. 7a). Renal tubules and glomeruli were histologically normal. The tubules were lined by columnar epithelium and Bowman’s capsules were normal and had normal glomeruli. Minimal changes were noticed in some areas in renal medulla. The renal pelvis also appeared normal.

**Fig. 7.** Photomicrograph of kidney of (a) control mouse showing normal structure, (b) CCl₄-treated mouse had vacuolar degenerative changes in the renal epithelium, (c) CCl₄-treated mouse had early necrotic changes, (d) CCl₄-treated mouse had congestion of renal blood vessels, (e) CCl₄-treated mouse had focal leucocytic infiltrations, (f) CCl₄-kefir treated mouse had moderate improvement of renal lesions and mild vacuolar degenerative changes in the renal epithelium with absence of necrotic changes, and (g) CCl₄-kefir treated mouse had mild congestion of renal blood vessels with no focal inflammatory reaction.
Histopathological examination revealed mild pathological alterations. The most common changes were hydropic degeneration of renal epithelium of some tubules (Fig. 7b) with mild congestion of some blood vessels (Fig. 7c). Early necrotic changes were demonstrated in outer cortex. Glomerulonephritis was seen some areas (Fig. 7d). Marked vacuolation was evident in renal medulla. No signs of an inflammatory reaction could be seen except in one case, which appeared as focal mononuclear cell infiltration in the renal cortex (Fig. 7e).

**CCl₄–treated group**

The histopathological changes in these animals were much less in comparing to the CCl₄-treated group. Renal tubules had minimal pathological changes (hydropic degeneration) in most areas with mild congestion and without inflammatory changes (Fig. 7f&g). The glomeruli showed no histopathologic alterations.

**Spleen**

In the control group, spleen appeared more or less normal at the level of white and red pulps (Fig. 8a).

**Statistical analysis**

All data were expressed as means ± standard error of the mean (S.E.M). Statistical analysis was done using statistical packages for social sciences (SPSS) computer software (version 22), IBM software, USA. One-way analysis of variance (ANOVA) test was used to elucidate significance among group means, followed by Tukey’s post-hoc test to compare mean values pair-wise. Differences were considered significant at \( p < 0.05 \).
DISCUSSION

Recently, there is a strong focus on beneficial foods with probiotic microorganisms and functional organic substances especially the commercial use of kefir. It may act as a matrix in the effective delivery of probiotic microorganisms in different types of products as it has a biological activity due to the presence of kefir’s exopolysaccharides, known as kefiran. Kefir is mainly considered a probiotic resource because of its composition. According to definition “Probiotics are microbial cell preparations or components of microbial cells with a beneficial effect on the health of the host”. Some studies suggest that probiotic bacteria in kefir consumers’ gut are increased and play an important role in health improvement.

The probiotic species, particularly lactobacilli are equipped for creating an extensive variety of antimicrobial mixes, counting natural acids (lactic and acidic acids), carbon dioxide, hydrogen peroxide, ethanol, diacetyl and peptides (bacteriocins) that can be helpful not just in diminishing sustenance pathogens and bacterial harm amid capacity and sustenance consumption, additionally in the treatment and counteractive action of gastrointestinal and vaginal infection. Kefiran has more advantages, comparing to other polysaccharides, such as bactericidal, fungicidal, antitumor properties, anti-inflammatory and promote healing, immunomodulation or epithelium protection and antioxidant activity.

Our results demonstrated that after 24 h as well as 48h, fermented kefir possesses high antibacterial activity against Gram-negative and Gram-positive including Staphylococcus aureus, E. coli and Salmonella Enteritidis. The antimicrobial activity was superior to control antibiotic, although exhibited no activity against P. aeruginosa and C. albican. These results agree with previous study which showed that kefir as a probiotic can restrain the action of coliform microscopic organisms, and some entero pathogenic microscopic organisms like Shigella sp., Salmonella sp., and of Gram-positive microorganisms, for example, S. aureus, Bacillus cereus, Clostridium sp. and Listeria monocytogenes.

In this study, isolated microorganism from kefir were closely related to Micrococcus cohnii (isolate ID SK14), Lactobacillus kefiranofaciens ZW3 (isolate ID SK22) and Lactobacillus casei strain KF11 (isolate ID SK23).

Micrococc, like many other representatives of the Actinobacteria, can be metabolically versatile, with the ability to utilize a wide range of unusual substrates, such as pyridine, herbicides, chlorinated biphenyls, and oil. They are likely involved in detoxification or biodegradation of many other environmental pollutants. Other Micrococcus isolates produce various useful products, such as long-chain (C_{21}-C_{14}) aliphatic hydrocarbons for lubricating oils.

An exopolysaccharide (EPS) producing strain, ZW3, was isolated from Tibet kefir grain and was identified as Lactobacillus kefiranofaciens. FT-IR spectroscopy revealed the presence of carboxyl, hydroxyl, and amide groups, which correspond to a typical hetero polymeric polysaccharide. The GC analysis of ZW3 EPS revealed that it was glucogalactan in nature.

Lactobacillus casei is a species of the genus Lactobacillus found in the human intestine and mouth. This particular species of Lactobacillus is documented to have a wide pH and temperature range, and complements the growth of L. acidophilus, a producer of the enzyme amylase (a carbohydrate-digesting enzyme).

Kefir was found to have a protective effect against CCl4-induced damage in liver, spleen and kidney. Histopathologically, compared to CCl4 treated mice, mild to moderate improvements in the form of absence of neither hepatic degeneration nor necrosis with sings of regeneration (increased mitotic activities and bi-nucleation). The hepatic sinusoids appeared also of normal appearance with mild. Renal tissues showed minimal degeneration. Spleen also showed marked improvement comparing to CCl4 treated animals.

Kefir has a histopathological preventive attribute in animal model as it lower the necrobiotic changes in acute renal injury. The adverse findings of CCl4 (hepatocellular damage and apoptosis) were reduced with kefir administration; this indicating that kefir has a protective role at liver damage. Also it has been found that no toxic effect of L. kefiranofaciens M1 was seen at the gross and microscopic histopathology of the organs (heart, liver, kidney, adrenal glands, spleen, ovary, and...
Kefir was chosen in our study as a potential protective agent because of its antioxidant and hepatoprotective activity. According results of this study, CCl$_4$ induced liver toxicity in mice and it is harmful to other organs such as kidney and spleen which was in the form of increased liver weight to body weight, elevated liver enzymes and alkaline phosphatase, an indication of structural and functional defects in liver cells. Marked improvement was evident with treatment with kefir as indicated by estimation of body weight and relative liver weight to body weight; the ratio of liver weight to 100 g body weight was significantly increased by sole administration of CCl$_4$ (1.9900±:13565, p <0.05) compared to control animals (1.1070±:04842). Interestingly treatment with both kefir and CCl$_4$ exhibited liver weight/100 g body weight ratio (1.3900±0.08741) which is significantly lower than CCl$_4$ group (p <0.05) and was close to normal value.

At the end of experiment, comparing the animal total body weight to its corresponding initial value, only CCl$_4$ group exhibited a significant decrease compared to its corresponding initial weight. Note northerly, the body weights exhibited by combination group had higher values compared to both its initial body weight and body weights exhibited by CCl$_4$-treated group, however, it is still less than the control value. Data were calculated as relative weight of liver to 100 g animal body weight at the end of the experiment. Data are presented as mean ± standard error of 10 animals/group.

Kefir effectively has protection against CCl$_4$-induced hepatotoxicity in mice. These protections are approved via the serum levels of liver functions (AST, ALT, and ALP). In the CCl$_4$ treated group, the serum levels of AST, ALT, and ALP p <0.05, were increased to 1372.6367 ± 2.06498, 1410.2500 ± 2.60688 and 251.4583 ± 16.79796 respectively compared to control values of liver functions (AST, ALT, and ALP). In conclusion, our findings revealed that kefir has antimicrobial activity against pathogenic microorganisms and protective properties against CCl$_4$-induced hepatotoxicity. These protective effects included anti-inflammatory effect and inhibition of CCl$_4$ activity with improving of liver functions. So, kefir may have the potential for clinical applications to the prevention and/or treatment of liver toxicity.

REFERENCES

1. Adriana, P., Socaciu, C. Probiotic activity of mixed cultures of kefir’s lactobacilli and non-lactose fermenting yeasts. Bull. UASVM Agri., 2008; 65: 329–334.
2. Saloff-Coste, C. Kefir. Danone World Newsletter, 1996; 11(4): 27.
3. Garrote, G.L., Abraham, A.G., De Antoni, G.L. Characteristics of kefir prepared with different grain [ratio] milk ratios. J. Dairy Res., 1998; 65(01): 149–154.
4. Loretan, T., Mostert, J., Viljoen, B. Microbial flora associated with South African household kefir. S. Afr. J. Sci., 2003; 99(1–2): 92–94.
5. Garrote, G.L., Abraham, A.G., De Antoni, G.L. Inhibitory power of kefir: the role of organic acids. J. Food Protect., 2000; 63(3) 364 - 369.
6. Duitschaever, C., Kemp, N., Emmons, D. Pure culture formulation and procedure for the production of kefir. Milchwissenschaf, 1987; 42(2): 80-82.
7. Farnworth, E.R. Keûr–a complex probiotic. Food Sci. Technol. Bull., 2006; 2(1): 1–17.
8. Dong, H., Dana, J., Hyunsook, K., Byeong, K. Antimicrobial Activity of Kefir against Various Food Pathogens and Spoilage Bacteria. Korean J. Food Sci. Anim. Resour., 2016; 36(6): 787–790.
9. Abraham, A.G., Antoni, G.L. Characterization of kefir grains grown in cows’ milk and in soya milk. J. Dairy Res., 1999; 66(02): 327–333.
10. Rattray, D.D., O’Connell, C.M., Baskett, T.F. Acute disseminated intravascular coagulation in obstetrics: a tertiary centre population review (1980 to 2009). J. Obstet. Gynaecol. Can., 2012; 34(4): 341–347.
11. Farnworth, E.R., Mainville, I. Kefir: a fermented milk product. Handbook of fermented functional foods, 2003; 2: 89–127.
12. Farnworth, E.R. The evidence to support health claims for probiotics. J. Nutr., 2008; 138(6): 1250-1254.
13. Garrote, G.L., Abraham, A.G., De Antoni, G.L. Microbial Interactions in Kefir: A Natural Probiotic Drink. Biotechnology of Lactic Acid Bacteria: Novel Applications, 2010; 327.

14. Mainville, L., Robert, N., Lee, B., Farnworth, E.R. Polyphasic characterization of the lactic acid bacteria in kefir. Syst. Appl. Microbiol., 2006; 29(1): 59–68.

15. Rattray, F., O’Connell, M. Fermented milks kefir. Encyclopedia of dairy sciences, 2011; 2: 518–524.

16. Shikongo-Nambabi, M.N.N.N., Shoolongela, A., Schneider, M. Control of bacterial contamination during marine fish processing. Journal of Bioglogy and Life Science, 2011; 3(1): 2157–6076.

17. Magalhães, K.T., Pereira, G.V.d.M., Campos, C.R., Dragne, G., Schwan, R.F. Brazilian kefir: structure, microbial communities and chemical composition. Braz. J. Microbiol., 2011; 42(2): 693–702.

18. Rea, M., Lemartsson, T., Dillon, P., Drinan, F., Reville, W., Hepes, M. Cogan, T. Irish kefir like grains: Their structure, microbial composition and fermentation kinetics. J. Appl. Bacteriol., 1996; 81(1): 83–94.

19. Leite, A.M.d.O., Miguel, M.A.L., Peixoto, R.S., Rosado, A.S., Silva J.T., Paschoalin, V.M. Microbiological, technological and therapeutical properties of kefir: a natural probiotic beverage. Braz. J. Microbiol., 2013; 44(2): 341–349.

20. Garrote, G., Abraham, A. De Antoni, G. Preservation of kefir grains, a comparative study. LWT- Food Sci. Technol., 2013; 51(1): 404–408.

21. Kaufmann, K.D. Kefir rediscovered. Alive Book, Burnhaby, 1997, 86.

22. Wswolek, M., Kupiec-Teahan, B., Guldager, H.S., Tamine, A. Production of kefir, koumiss and other related products. Fermented milks, 2006; 174–216.

23. Odet, G. Fermented milks. Bulletin-Int. Dairy Federation, 1995; (300): 98–100.

24. Lazar, V., Baloescu, M.C., Vassu, T., Barbu, V., Smarandache, D., Sasaran, E., Israil, A., Bulai, D., Alexandru, I. Cernat, R. Experimental Study on Rats of the Probiotic Effect of Some Lactic Acid Bacteria Previously Selected for their In Vitro Capacity to Interfere with Salmonella enteritidis Infection. Roum. Biotech. Lett., 2005; 10: 2123–2133.

25. Chifiriuc, M.C., Stecoza, C., Dracea, O., Larion, C., Israil, A. Anti-microbial activity of some new O-acetyl-ximino-dibenzo [b, e] thiepins and O-acetyl-ximino-dibenzo [b, e] thiepin-5, 5-dioxides against planktonic cells. Roman. Biotechnol. Lett., 2010; 15(2): 5134-5139.

26. Ahmed S.H., Amin, M.A., Saafan, A.E., El-Gendy, A.O., Ul Islam, M. Measuring susceptibility of Candida albicans biofilms towards antifungal agents. J. Microbiol. and Biotechnol. Res., 2017; 3(1): 149–156.

27. Ahmad, M.S., El-Gendy, A.O., Ahmed, R.R., Hassan, H.M., El-Kabbany, H.M., Merdash, A.G Exploring the Antimicrobial and Antitumor Potentials of Streptomyces sp. AGM12-1 Isolated from Egyptian Soil. Front. Microbiol., 2017; 8.

28. Tamura, K. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Molec. Biol. Evolu., 2007; 24(8): 1596-1599.

29. Aspiras, B.E.E., Flores, R.F.A.C., Pareja, M.C. Hepatoprotective effect of Fermented Water Kefir on Sprague-Dawley rats (Rattus norvegicus) induced with sublethal dose of Acetaminophen. Int. J. Curr. Sci., 2015; 17: 18–28.

30. Bancroft, J.D., Gamble, M. Theory and practice of histological techniques. Elsevier Health Sciences, 2008 p.

31. Nalbantoglu, U., Cakar, A., Dogan, H., Abaci, N., Ustek, D., Sayood, K., et al. Metagenomic analysis of the microbial community in kefir grains. Food Microbiol., 2014; 41: 42–51.

32. Zheng, Y., Lu, Y., Wang, J., Yang, L., Pan, C., Huang, Y. Probiotic properties of Lactobacillus strains isolated from Tibetan Kefir grains. PLoS ONE, 2013; 8:e69868.

33. Cevikbas, A., Yemni, E., Ezzedenn, F.W., Yardimici, T., Cevikbas, U., Stohs S.J. Antitumoural, antibacterial and antifungal activities of kefir and kefir grain. Int. J. Biol. Macromol., 2010; 3(8): 1596-1599.

34. Wang, Y., Ahmed, Z., Feng, W., Li, C., Song, S. Physicochemical properties of exopolysaccharide produced by Lactobacillus kefiranofaciens ZW3 isolated from Tibet kefir. Int. J. Biol. Macromol., 2008; 43: 283–288.

35. Rodrigues, K.L., Caputo, L.R.G., Carvalho, J.C.T., Evangelista, J., Schneefeld, J.M. X Antimicrobial and healing activity of kefir and kefirian extract. Int. J. Microbiol. Agents, 2005a; 25: 404–408.

36. Rodrigues, K.L., Carvalho, J.C.T., Schneefeld, J.M. Anti-inflammatory properties of kefir and its polysaccharide extract. Inflammopharmacology, 2005b; 13: 485–492.

37. Serafini, F., Turroni, P., Ruas-Madiedo, G.A., Lugli, C., Milani, S., Duranti, N., et al. Kefir fermented milk and kefirian promote growth of Bifidobacterium bifidum PRL2010 and modulate its gene expression. Int. J. Food Microbiol, 2014; 17850–59.

38. Chen Z., Shi J., Yang X., Nan B., Liu Y., Wang J. Pure Appl. Microb., 11(2), JUNE 2017.
Z. Chemical and physical characteristics and antioxidant activities of the exopolysaccharide produced by Tibetan kefir grains during milk fermentation. *Int. Dairy J.*, 2015; **43**: 15–21.

39. Van Wyk, J. The inhibitory activity and sensory properties of kefir, targeting the low-income African consumer market, Stellenbosch: Stellenbosch University, 2000.

40. Yanping, W., Jingrui, W., Zaheer, A., Xiaojia, B. Complete Genome Sequence of *Lactobacillus kefiranofaciens* ZW3. *J. Bacteriol.*, 2011; **193**(16): 4280–4281.

41. Ozsoy, ^.Y. The Protective Effect of Kefir on Carbon Tetrachloride-induced Histopathological Changes in the Livers of Rats. *Kafkas Universitesi Veteriner Fakultesi Dergisi*, 2016; **22**(3): 403-408.

42. Owaga, E.E., Chen, M.J., Chen, W.Y., Chen, C.W., Hsieh, R.H. Oral toxicity evaluation of kefir-isolated *Lactobacillus kefiranofaciens* M1 in Sprague-Dawley rats. *Food Chem. Toxicol.*, 2014; **70**:157-62.

43. Saitou, N., Nei, M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. *Molec. Biol. Evolu.*, 1987; **4**(4): 406-425.

44. Kimura, M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. *J. Mol. Evol.*, 1980; **16**(2): 111-120.

45. Kumar, S., Stecher, G. Tamura, K. MEGA7 2016: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Molecular biology and evolution, 2016; **54**.